Equity Details
Price & Market Data
Price: $7.30
Daily Change: +$0.21 / 2.88%
Daily Range: $7.03 - $7.37
Market Cap: $708,306,752
Daily Volume: 50,283
Performance Metrics
1 Week: -6.17%
1 Month: -5.07%
3 Months: -8.41%
6 Months: 1.25%
1 Year: -32.59%
YTD: 3.40%
About Gyre Therapeutics, Inc. (GYRE)
Explore Gyre Therapeutics, Inc. (GYRE)'s performance at a glance. Current price: 7.30, daily change: +$0.21 / 2.88%. Market cap: 708,306,752. Focus on its YTD and 3-month performance.
Company Details
Employees: 625
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.